Abstract
Multiple myeloma (MM) is a clonal B-cell cancer of proliferating plasma cells. It represents nearly a tenth of all hematologic malignancies. Renal dysfunction is present in 25–50 % of newly diagnosed MM patients, about 9 % of which needs hemodialysis (HD). Cast nephropathy is determined by an overflow of filtered serum-free light chains (sFLC) in the proximal tubule that largely overwhelms its endocytic capacity. Bortezomib-based regimens, including high-dose dexamethasone, are recommended as first-choice therapy. In addition, kidney exposure to sFLC may be reduced with extracorporeal sFLC removal. Plasma exchange has been for long time the only extracorporeal technique used in cast nephropathy, but it is now not recommended for sFLC removal in patients with MM-associated AKI. In recent years, other techniques such as HD with new generation high cutoff dialyzers showed their efficacy in sFLC removal and should now be considered for a more rapid reduction of sFLC levels in combination with bortezomib-based therapies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351(18):1860–1921
Knudsen LM, Hippe E, Hjorth M et al (1994) Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur Haematol 53(4):207–212
Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for diagnosis of multiple myeloma. Lancet Oncol 15(12):e538–e548
Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33
Blade J, Fernandez-Llama P, Bosch F et al (1998) Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158(17):1889–1893
Davenport A, Merlini G (2012) Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities. Nephrol Dial Transplant 27(10):3713–3718
Mhaskar R, Redzepovic J, Wheatley K et al (2010) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (5):CD003188
Dimopoulos MA, Terpos E, Chanan-Khan A et al (2010) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 28:4976–4984
Landoni G, Bove T, Székely A et al (2013) Reducing mortality in acute kidney injury patients: systematic review and international web-based survey. J Cardiothorac Vasc Anesth 27(6):1384–1398
Zucchelli P, Pasquali S, Cagnoli L, Ferrari G (1988) Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33:1175–1180
Clark WF, Stewart AK, Rock GA et al (2005) Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 143(11):777–784
Gupta D, Bachegowda L, Phadke G et al (2010) Role of plasmapheresis in the management of myeloma kidney: a systematic review. Hemodial Int 14:355–363
Leung N, Gertz MA, Zeldenrust SR et al (2008) Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 73(11):1282–1288
Hutchison CA, Cockwell P, Reid S et al (2007) Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo study. J Am Soc Nephrol 18:886–895
Hutchison CA, Heyne N, Airia P et al (2012) Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant 27(10):3823–3828
Johnson WJ, Kyle RA, Pineda AA et al (1990) Treatment of renal failure associated with multiple myeloma plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150(4):863–869
Fabbrini P, Sirtori S, Casiraghi E et al (2013) Polymethylmethacrylate membrane and serum free light chain removal: enhancing adsorption properties. Blood Purif 35(Suppl 2):52–58
Pasquali S, Iannuzzella F, Corradini M et al (2015) A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR). J Nephrol 28(2):251–254
Hutchison CA, Cook M, Heyne N et al (2008) European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial. Trials 9:55
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Paternoster, G., Fabbrini, P., Attolico, I. (2016). Extracorporeal Removal of Serum-Free Light Chains in Patients with Multiple Myeloma-Associated Acute Kidney Injury. In: Landoni, G., Pisano, A., Zangrillo, A., Bellomo, R. (eds) Reducing Mortality in Acute Kidney Injury. Springer, Cham. https://doi.org/10.1007/978-3-319-33429-5_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-33429-5_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33427-1
Online ISBN: 978-3-319-33429-5
eBook Packages: MedicineMedicine (R0)